Carfilzomib Is Safe and Effective in Newly Diagnosed Patients with Multiple Myeloma with Renal Involvement

被引：0
|
作者：
Diamond, Benjamin
Jayabalan, David S.
Pearse, Roger
Perry, Art
Pekle, Karen
Niesvizky, Ruben
Rossi, Adriana C.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3102
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Impact of Renal Impairment Criteria on Survival of Patients With Newly Diagnosed Multiple Myeloma
    Strufaldi, Fernando L.
    Segura, Gabriela C.
    Caires, Renato A.
    Mattedi, Francisco Z.
    Costalonga, Elerson
    Martinez, Gracia
    Costa e Silva, Veronica T.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 643 - 643
  • [32] Prognostic impact of renal failure recovery in patients with newly diagnosed multiple myeloma
    Pena, Camila
    Valladares, Ximena
    Gajardo, Claudia
    Russo, Moises
    Morales, Alvaro
    Correa, Gonzalo
    Valjalo, Ricardo
    REVISTA MEDICA DE CHILE, 2019, 147 (11) : 1374 - 1381
  • [33] A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma
    Bringhen, Sara
    Cerrato, Chiara
    Petrucci, Maria Teresa
    Genuardi, Mariella
    Gentilini, Fabiana
    Conticello, Concetta
    Oliva, Stefania
    Pantani, Lucia
    Offidani, Massimo
    Palladino, Carmela
    Benevolo, Giulia
    Montefusco, Vittorio
    Astolfi, Monica
    Villani, Oreste
    Siniscalchi, Agostina
    Rocci, Alberto
    De Paoli, Lorenzo
    Boccadoro, Mario
    Sonneveld, Pieter
    Palumbo, Antonio
    BLOOD, 2013, 122 (21)
  • [34] Case reports: Central nervous system involvement in patients with newly diagnosed multiple myeloma
    Liu, Jinghua
    Shen, Jing
    Liu, Daihong
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [35] A phase 1/2 study of carfilzomib, bendamustine, and dexamethasone (CBD) in newly diagnosed multiple myeloma patients.
    Leng, Siyang
    Wei, Alexander
    Assal, Amer
    Bhutani, Divaya
    Baliko, Gregory
    Gould, Julia
    Shelton, Ryan J.
    Kelly, Shannon
    Otap, Daniel
    Mapara, Markus Y.
    Lentzsch, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] A PHASE I/II TRIAL OF CYCLOPHOSPHAMIDE, CARFILZOMIB, THALIDOMIDE AND DEXAMETHASONE (CYCLONE) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Mikhael, J.
    Reeder, C.
    Libby, E.
    Costa, L.
    Mayo, A.
    Bergsagel, L.
    Buadi, F.
    Pirooz, N.
    Lubben, J.
    Dueck, A.
    Stewart, A.
    HAEMATOLOGICA, 2012, 97 : 119 - 119
  • [37] Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone
    Loncharich, Alexa J.
    Fiala, Mark A.
    Slade, Michael J.
    Vickroy, Angela
    Kavanaugh, Margaret
    Wilson, Carmen
    Schroeder, Mark A.
    Stockerl-Goldstein, Keith
    Vij, Ravi
    Sanfilippo, Kristen M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (11): : 825 - 828
  • [38] Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone
    Loncharich, Alexa J.
    Fiala, Mark A.
    Slade, Michael J.
    Vickroy, Angela
    Kavanaugh, Margaret
    Wilson, Kari
    Schroeder, Mark A.
    Stockerl-Goldstein, Keith E.
    Vij, Ravi
    Sanfilippo, Kristen M.
    BLOOD, 2022, 140 : 8550 - 8551
  • [39] Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone
    Manasanch, Elisabet E.
    de larrea, Carlos Fernandez
    Zingone, Adriana
    Steinberg, Seth M.
    Kwok, Mary
    Tageja, Nishant
    Bhutani, Manisha
    Kazandjian, Dickran
    Roschewski, Mark
    Wu, Peter
    Carter, George
    Zuchlinski, Diamond
    Mulquin, Marcia
    Lamping, Liz
    Costello, Rene
    Burton, Deborah
    Gil, Lindsay A.
    Figg, William D.
    Maric, Irina
    Calvo, Katherine R.
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    Korde, Neha
    Landgren, Ola
    LEUKEMIA & LYMPHOMA, 2017, 58 (03) : 639 - 645
  • [40] Asciminib is safe and effective in patients with newly diagnosed CML
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (08) : 566 - 566
12345